Arctic Bioscience - Report Publication Announcement 2022

Arctic Bioscience - Invitation to presentation of half year 2022 results

Arctic Bioscience will publish its financial results for the half year 2022 on

Thursday 25 August, at 08:00 CET.

The same day at 10:00 CET, the Company will host a webcast to present the

results. Following the presentation, it will be opened for questions from the

audience.

Webcast details:

Date: Thursday 25 August 2022

Time: 10:00 CET

Format: Webcast and Q&A

Language: English

Link: https://channel.royalcast.com/landingpage/hegnarmedia/20220825_11/

Participants will be required to register to view the webcast and participate in

the Q&A.

For further information, please contact:

Christer L. Valderhaug

CEO of Arctic Bioscience AS

Mobile: +47 920 84 601

Jone R. Slinning

CFO of Arctic Bioscience AS

Mobile: +47 948 75 469

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in

developing marine oils and experience from global pharmaceutical companies.

AI assistant